Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
LOL, Looking at that sight myself. Thanks for posting it to the scapple. May use it from time to time to confirm- or change- my T/A reading. I'm still learning this stuff and find it interesting
Thanks Arch. Its just one of many out there, LOL. The search continues....
Thanks Arch. I noticed the williams and strength turning upward. Usually a sign of a reversal, no?
Some good advice in between the lines here.
An Overlooked Fund That Delivers Results
Sat Feb 23, 8:33 AM ET
By Clint Willis
BOSTON (Reuters) - Chances are, you've never heard of the Boyar Value Fund -- which is your loss. The fund has been an extremely strong performer since its inception in late 1998, and its lack of recognition by investors says a lot about what could be wrong with the mutual fund industry.
The fund is managed by New York City money manager Mark Boyar, one of the most distinguished value investors of the last three decades. Like other great value investors -- from Michael Price to Warren Buffett -- Boyar has a well-defined strategy and sticks to it, regardless of market fads.
That strategy calls for buying stock in corporations that trade below their intrinsic value.
Intrinsic value can be a slippery term, but Boyar offers a clear definition: Intrinsic value is the amount shareholders would receive if that entire enterprise were liquidated or acquired by another firm.
Boyar and his research staff of four evaluate a company's intrinsic value as if they're business executives who are thinking about buying the entire company. The painstaking process involves tearing apart a company's balance sheet in search of values that are overlooked by Wall Street.
Such values often take the form of hidden assets like real estate, timber holdings, cellular franchises or inventory reserves. Thanks to the vagaries of accounting, those assets and others like them may be carried on a firm's books at sizable discounts to their actual market value.
Boyar and his staff also give careful consideration to the value of a company's franchises: products or services that have earned a high degree of consumer recognition, which in turn gives a firm an advantage over potential competitors.
Many of Boyar's most successful stock picks have been overlooked by his peers at better-known mutual funds. That's because he devotes considerable attention to studying the earnings power and assets of firms whose shares have fallen from favor in the investment community.
For example, he sometimes buys shares in companies that have fallen from favor due to temporary setbacks, as well as firms that are engaged in complex restructurings, break-ups and spin-offs. Boyar notes that even bankruptcies offer potential rewards, and he doesn't hesitate to seek out those profits on behalf of shareholders.
Boyar's skill at finding undervalued companies has led to superb returns for his various private accounts over the last three decades. Over the past five years, Boyar Partners Limited Fund has returned 17.17 percent. That compares with 11 percent for the Dow, and 10.70 percent for the S&P 500. The Fund has a 10-year annualized return of about 15.6 percent, versus 13 percent for the S&P 500.
The Boyar Value Fund is also off to a rip-roaring start, with a 7.6 percent annual gain since its inception in late 1998; that compares with a 1.9 percent annual return for the S&P 500. Last year, the fund posted a 15.3 percent return, outstripping the S&P 500 by a full 27 percentage points.
What's more, Boyar's low turnover approach delivered exceptionally strong after-tax returns. The fund gained 15.3 percent after taxes last year -- identical to its pre-tax return!
So why does this superb fund boast a mere $12 million in assets? One reason is that investors were sidetracked by high-flying technology funds during the first year or two of the fund's existence: Back in 1999, the average technology fund gained 135 percent, which made that a difficult time for a new value fund to gain investors' notice.
Unfortunately, however, there are other barriers that keep promising new funds from getting the attention and the assets they deserve. Most large mutual funds spend enormous sums on large sales forces and marketing campaigns, and you can be sure that if one of them owned the Boyar Value fund, they would be heavily promoting its sterling record.
By contrast, Boyar spends almost nothing on marketing, so you're not likely to see the fund's name pop up in television or print advertisements.
Worse, the fund can't afford to get on the preferred lists of full-service brokers. No matter how strong a fund's record, it can't get on those lists unless it makes an upfront payment, known as revenue sharing, to the broker.
"Revenue sharing essentially means that the full-service brokers are being paid to favor certain funds over others," says Boyar.
Moral: Don't expect to hear about Boyar Value from your full-service broker. Instead, you're much more likely to hear about a fund that already has garnered sizable assets, thanks in part to a fund company's powerful marketing machine.
The brokers' neglect of funds such as Boyar Value is good news for astute investors. The fund's small size adds to its flexibility, allowing Boyar to pick his shots carefully and buy only his favorite stocks.
By contrast, larger funds have to spread huge sums of cash around a larger universe of stocks, invariably including a fair number of mediocre picks.
The bottom line: You don't have to wait for a broker to tell you which funds to buy, and practices such as revenue sharing mean that maybe you shouldn't.
Instead, spend some time browsing Web sites such as Morningstar.com (http://www.Morningstar.com) in search of overlooked funds whose sponsors spend more money on research than on advertising. Additional information is available by contacting Boyar Asset Management at 800-266-5566.
http://story.news.yahoo.com/news?tmpl=story&cid=580&u=/nm/20020223/bs_nm/column_funds_dc_8
Good Morning,
Looking at a few charts and thought these may worth looking at:
PRCS @$4.58- bollies are tight, could go either way (drug company). I'll continue to watch.
http://www.askresearch.com/cgi-bin/chart?symbol=prcs&country=USA&size=640x480&months=6+m...
CYLK @$1.95- money flow is rising, but everything else looks like downward movement. I would watch the Stochastic to see if it holds. My guess is an entrty around $1.80. Target $2.50-$2.80 range. (information security products)
http://www.askresearch.com/cgi-bin/chart?symbol=cylk&country=USA&size=640x480&months=6+m...
DAKT @$6.54- looks to be still downtrending to me. I've been watching this one for a while. Good company. They make the big screens for stadiums and such. T/A wise, I think it will test the $6 support. Rate of change and relative strength are turning positive, and the williams is trying to turn also. Entry would be around $6 and a target of $9ish.
http://www.askresearch.com/cgi-bin/chart?symbol=dakt&country=USA&size=640x480&months=6+m...
Feedback and comments welcome. I'm still learning this stuff. Thanks.
Matt, Your Mom should be proud of you. Excellent post. Thanks for all you do- Tim
sarals, check this board out. Read the Ibox. It is an extension of our on-line club. If you like what you see. email me (timhyma@yahoo.com) and I will send you an invite to the private yahoo club.
http://www.investorshub.com/boards/board.asp?board_id=865
Went to the Hot! link on the upper right of my screen
Noticed the same problem here
http://www.investorshub.com/boards/board.asp?board_id=865
Interesting site-
Companies we focus on:
Insidetruth.com focuses on primarily with over-hyped, overvalued, fraudulent, promoted, spammed, or suspect equities.
These are the type of companies that have rapid run ups, and often trap unknowing investors in Securities that do not hold stable values over time.
In the world of investing, these stocks are often the most risky to individual investors, yet receive the least amount of attention. Many analysts make the most generic comments that "investing is risky." The goal of focusing on the companies we do is to illuminate these risks to investors, to educate them, and finally to help investors avoid unnecessary risks they may not be prepared to handle.
http://www.insidetruth.com/
I think- Mcdonald-Douglas?
Insidetruth.com focuses on primarily with over-hyped, overvalued, fraudulent, promoted, spammed, or suspect equities.
http://www.insidetruth.com/
Even found a Ihubber mentioned in here.
NW,
Don't know of them- yet. I have been looking around for a company in this industry though. I am in the military, and I feel that we will see in significant increase in the need for cargo type aircraft (C-5 and C-17). The Air Force is having a hard time meeting mission on moving the military might. With the big defense budget- I speculate that a big piece will go in the direction
I found this one funny as they say "This is not spam. Your name was provided by KBFP". I never heard of this company.
Date: Sat, 23 Feb 2002 14:11:10 -0800
From: "OTCBB News Network" <DMCLLC@yahoo.com> / Block Address / Add to Address Book
Subject: KPF Pollution Management Media Interview
To: "KBFP Investors" <DMCLLC@yahoo.com>
Reply-to: DMCLLC@yahoo.com
OTCBB News Network Interviews President of KBF Pollution Management,
Inc.
The modern economy has caused some serious industrial waste problems.
KBF Pollution Management, Inc. (KBFP: .09) has developed and refined a
cost efficient industrial resource recovery technology. We had an
informative discussion with Kevin Kreisler, President of KBFP. (February 22,
2002-- 11 min)
http://www.otcbbnn.com/radio-broadcasts.htm
This is not spam. Your name was provided by KBFP. To be removed from
this list simply send a "remove" to office@OTCBBNN.com
Disclaimer:
International Broadcasting Corporation ("IBC") is an independent
electronic publication providing information on selected public companies.
IBC is not a registered investment advisor or a broker dealer. IBC has
been advised that the investments in companies discussed are considered
to be high risk, and use of the information provided is at the
investor's sole risk.
IBC has also been advised that the purchase of such high risk
securities may result in the loss of some or all of the investment. The
information provided by the companies reported on may include information
provided by outside sources, such as research reports, public filings or
computer databases and information provided to IBC by management of the
companies reported on. All information is obtained from sources believed
to be reliable, including company press releases, SEC Filings and other
sources, and IBC makes no representations, warranties or guarantees as
to the accuracy or completeness of the information or the disclosure by
the companies reported on. Investors should not rely solely on the
information presented. Rather, investors should use the information
regarding companies as a starting point for doing additional independent
research on the companies in order to allow the investor to form his or her
own opinion regarding investing in the companies that are reported on.
Factual statements made by the companies reported on are made as of the
date stated and are subject to change without notice. The receipt of
this information shall not create, under any circumstances, any
implication that there has been no change in the affairs of the company reported
on since the date of review. Investing in micro-cap securities is
highly speculative and carries an extremely high degree of risk. It is
possible that an investors entire investment may be lost or impaired due to
the speculative nature of the companies reported on. IBC makes no
recommendation that the securities of the companies reported on should be
purchased, sold or held by individuals or entities that learn of the
companies through IBC. Investing in micro-cap securities is highly
speculative and carries an extremely high degree of risk. It is possible that
an investor's investment may be lost or impaired due to the speculative
nature of the companies reported on. None of the securities discussed
should be construed as an offer to sell securities.
The Corporate Reporter section is a special advertising section that
features information that is not a part of the regular news content. The
Corporate Snapshot is an audio feature that appears as a part of a
Corporate Reporter advertising campaign. The Corporate Snapshot audio
feature may appear anywhere on our website, including the Radio Broadcasts
section or even the front page. Information presented in both of these
sections is provided by the advertisers, not our reporters. KBF
Pollution Management, Inc. (KBFP) has compensated IBC $2,500 in cash for a one
month advertising campaign in the Corporate Reporter section starting
January 23, 2002. It is possible that our advertising clients could
appear on the regular OTCBB News Network feeds as well as other web areas
like the "OTCBB Directory" or other areas under development. Our policy
for advertisers that may appear in our news is that we will make every
attempt to apply exactly the same independent and unbiased journalistic
standards to these companies as we do to all OTCBB companies. The same
disclaimer information contained above that applies to all companies
that appear in our news also applies to advertising clients
Morningstar Alert
WCOM
02-23-02 02:02 AM
Stock Financial Health Grade change
The Morningstar Financial Health Stock Grade has changed from B to B+.
http://quicktake.morningstar.com/Stock/mstockgrades.asp?Country=USA&Symbol=WCOM
http://quicktake.morningstar.com/AlertNewsWire/ticker.asp?ticker=WCOM&alert=A0705
Glad I bought a little more this past week.
PE X earning X quick ratio. I then like to average it out by using the industry and sector also.
Look at Shaw Group (SGR) that you mentioned.
http://biz.yahoo.com/p/s/sgr.html
See the 12 month earning at $1.59?
Now here is where you get your PE and ratios-
http://yahoo.marketguide.com/MGI/mg.asp?target=/stocks/companyinformation/ratio&Ticker=SGR
Quick ratios= Company (1.34), Industry (1.46), and Sector (0.80)
12.39 X 1.59 X 1.34= $26.40
12.39 X 1.59 X 1.46= $28.76
12.39 X 1.59 X 0.80= $15.76
Add the totals, then divide by three= $23.64
And remember, as Josh pointed out, the PE could change.
Disclaimer- This is just a guide that I use, and claim no great knowledge of investing, LOL. I only do this for fun.
Good day to Arch and all. I have been remiss in my activity here. Busy at work and posting mostly on the BTS thread. Anyone here follow INTD? Any thoughts.
http://www.askresearch.com/cgi-bin/chart?symbol=intd&country=USA&size=640x480&months=6+m...
This is what I posted on 10 Jan-
Tightening bands, Higher lows, lower highs, money flow downtrending, strength weakening, on balance volume… Looks to me like it may be headed south. The plus side is insider buys. Yahoo says 5%, while quicken shows 16%. Thomsons have a super buy signal on the 7th, so- will it buck the trend? I doubt it, LOL , but might be a Feb buy- putting it on next month’s watch list
INTD
Intelidata Technologies develops and markets software products and consulting services for the financial services industry. The Company supplies Internet banking, electronic bill presentment and payment software to financial institutions that want to provide their own remote banking services. The Company also serves as an Application Service Provider by providing Internet hosting and service bureau solutions to financial institutions, including bankcard issuers.
For the nine months ended 9/01, revenues totalled $12.8 million, up from $4.5 million. Net loss from continuing operations totalled $26.4 million vs. income of $31.3 million. Results reflect increased consulting and services revenues, offset by decreased realized gains on investment sales.
Recent Price $2.90
Book Value (mrq) $0.85
Total Cash (mrq) $9.29M
Shares Outstanding 46.0M Float 43.7M
Shares Short 3.05M Percent of Float 7.0%
Insider and 5%+ Owners: 5%
85 institutions
Of the 46.0 million of shares outstanding, 7.60 million are owned by insiders so insider holdings account for 16.5% of the company stock.
InteliData Technologies Corporation, a small-cap growth company in the technology sector, is expected to underperform the market over the next six months with above average risk.
Shares are neither being accumulated heavily nor sold heavily by financial institutions. Neutral for a small company like INTD
The price-to-sales multiple is significantly higher than the average for all stocks in the StockScouter universe. Negative for a small company like INTD
The StockScouter measure of relative price change and consistency is very low. Very negative
Over the next 1-2 months, StockScouter forecasts that growth stocks will be in favor, small-cap stocks will be in favor, and technology stocks will be neutral
1-6 weeks trading
TARGET 1 Price: 4.01 Profit: 40.7%
POTENTIAL Good
Stop Limit/Trailing Stop Limit: 2.63
TARGET 1 Price: 1.91 Profit: 33%
POTENTIAL Excellent
Cover Limit/Trailing Cover Limit: 3.1
TARGET 2 Price: 1.59
http://www.stockconsultant.com/consultnow/basic.cgi?symbol=intd
Trendspotter= sell
http://quotes.barchart.com/texpert.asp?sym=intd&Submit=Enter&code=BSTCZ
Support Price (5day): $2.860 Support Price (20day): $2.700 Support Price (50day): $2.700 Support Price (100day): $2.700
Resistance Price (5day): $2.950 Resistance Price (20day): $3.030 Resistance Price (50day): $3.800 Resistance Price (100day): $5.000
http://www.knobias.com/individual/research/techanalysis.htm?ticker=INTD&coid=
InteliData Technologies Corporation, a Delaware corporation ("InteliData"), closed on the private placement sale of an aggregate of 2,712,727 shares of its common stock for a price per share of $2.75 per share, and warrants exercisable for the purchase of 1,356,364 shares of its common stock, at an exercise price per share of $2.75 per share, resulting in gross proceeds of approximately $7,460,000. The placement agent in the transaction received approximately $447,600 in commissions and a warrant to purchase 271,273 shares of InteliData's common stock for a price per share of $2.75 per share. Neither the shares nor the warrants sold have been registered under the Securities Act of 1933 (the "Act"), and were offered in reliance upon the exemption under Section 4(2) of the Act and the provisions of Regulation D promulgated thereunder. The net funds raised will be used for general corporate purposes.
http://biz.yahoo.com/prnews/011204/dctu013_1.html
Charts:
http://www.clearstation.com/cgi-bin/details?Symbol=intd&Refer=http://www.clearstation.com/
Not saying they don't have any cash (or equivlants), just that one of the things that I look at when doing an overview of a stock-
Financial Strength
Current Ratio (mrq*) 0.82
Debt/Equity (mrq*) 1.80
Total Cash (mrq) $0
http://biz.yahoo.com/p/a/aep.html
I may be way off here, You have been doing this a lot longer than me my friend <g>.
SGR looks like one to put in the portfolio to me.
SGR
The Shaw Group Inc. (Shaw) is a vertically integrated provider of complete piping systems and comprehensive engineering, procurement and construction services to the power generation industry. Shaw has supplied fabricated piping systems in over 375 power plants with an aggregate generation capacity in excess of 200,000 megawatts of piping systems in the United States and worldwide. The Company also provides services to the process industries (including petrochemical, chemical and refining industries), and the environmental and infrastructure industries.
For the three months ended 11/30/01, sales rose 8% to $453.6 million. Net income rose 56% to $19 million. Revenues reflect increased sales to power generation customers in the U.S. and Europe. Earnings also reflect the absence of $3.8 million in goodwill amortization charges
Recent Price $20.02
Book Value (mrq) $15.00
Total Cash (mrq) $543.6M
Profit Margin (ttm) 4.3% Operating Margin (ttm) 7.2%
Market Capitalization $801.9M Shares Outstanding 40.1M Float 36.8M
Shares Short 5.57M Percent of Float 15.1%
Insider and 5%+ Owners: 8%
2 insider buys; (always nice when the CFO buys at Market)
537 institutions Institutional: 95% (103% of float)
Doing a quick ratio valuation on this one- I come up with a value of $24.35. With the short interest, and overage of institution interest, I would not be surprised to see this near $30 in the next 3 months.
Chart- lots of positive indicators. Only caution that I see is stochastic are high and could is a dip near term.
http://www.askresearch.com/cgi-bin/chart?symbol=sgr&country=USA&size=640x480&months=6+mo...
5 Day Support $19.59 5 Day Resistance $20.16 15 Day Support $17.89 15 Day Resistance $20.50 80 Day Support $17.89 80 Day Resistance $29.80
Shaw Group Inc., a small-cap value company in the capital goods sector, is expected to outperform the market over the next six months with above average risk.
The price-to-earnings multiple is lower than average for all stocks in the StockScouter universe. Positive
The StockScouter measure of relative price change and consistency is low. Negative
Previous day's closing price for SGR was slightly below its 50-day moving average. Negative
Shares are under heavy accumulation by financial institutions. Positive for a small company like SGR
Analyst coverage: 7 (5 strong buy, 1 buy, 1 hold)
12 month target- $35- $71
Consensus 50
Short term by stockconsultant
TARGET 1 Price: 23.58 Profit: 13.6%
POTENTIAL Good
Stop Limit/Trailing Stop Limit: 19.08
Downside trading
TARGET 1 Price: 15.98 Profit: 23%
POTENTIAL Fair
Cover Limit/Trailing Cover Limit: 21.7
TARGET 2 Price: 14.63
SGR
The Shaw Group Inc. (Shaw) is a vertically integrated provider of complete piping systems and comprehensive engineering, procurement and construction services to the power generation industry. Shaw has supplied fabricated piping systems in over 375 power plants with an aggregate generation capacity in excess of 200,000 megawatts of piping systems in the United States and worldwide. The Company also provides services to the process industries (including petrochemical, chemical and refining industries), and the environmental and infrastructure industries.
For the three months ended 11/30/01, sales rose 8% to $453.6 million. Net income rose 56% to $19 million. Revenues reflect increased sales to power generation customers in the U.S. and Europe. Earnings also reflect the absence of $3.8 million in goodwill amortization charges
Recent Price $20.02
Book Value (mrq) $15.00
Total Cash (mrq) $543.6M
Profit Margin (ttm) 4.3% Operating Margin (ttm) 7.2%
Market Capitalization $801.9M Shares Outstanding 40.1M Float 36.8M
Shares Short 5.57M Percent of Float 15.1%
Insider and 5%+ Owners: 8%
2 insider buys; (always nice when the CFO buys at Market)
537 institutions Institutional: 95% (103% of float)
Doing a quick ratio valuation on this one- I come up with a value of $24.35. With the short interest, and overage of institution interest, I would not be surprised to see this near $30 in the next 3 months.
Chart- lots of positive indicators. Only caution that I see is stochastic are high and could is a dip near term.
http://www.askresearch.com/cgi-bin/chart?symbol=sgr&country=USA&size=640x480&months=6+mo...
5 Day Support $19.59 5 Day Resistance $20.16 15 Day Support $17.89 15 Day Resistance $20.50 80 Day Support $17.89 80 Day Resistance $29.80
Shaw Group Inc., a small-cap value company in the capital goods sector, is expected to outperform the market over the next six months with above average risk.
The price-to-earnings multiple is lower than average for all stocks in the StockScouter universe. Positive
The StockScouter measure of relative price change and consistency is low. Negative
Previous day's closing price for SGR was slightly below its 50-day moving average. Negative
Shares are under heavy accumulation by financial institutions. Positive for a small company like SGR
Analyst coverage: 7 (5 strong buy, 1 buy, 1 hold)
12 month target- $35- $71
Consensus 50
Short term by stockconsultant
TARGET 1 Price: 23.58 Profit: 13.6%
POTENTIAL Good
Stop Limit/Trailing Stop Limit: 19.08
Downside trading
TARGET 1 Price: 15.98 Profit: 23%
POTENTIAL Fair
Cover Limit/Trailing Cover Limit: 21.7
TARGET 2 Price: 14.63
Josh- Don't like companies that have $0 cash in the financial strength column. Also, if you do a quick ratio valuation, comes to just under $7.
Disclaimer- Looked only at the yahoo link provided <g>
May want to double check you filing
Rebate's Revenge? Tax Form Line Confuses
Sat Feb 23, 8:28 AM ET
WASHINGTON (Reuters) - Treasury Secretary Paul O'Neill has declared the complex U.S. income tax code an "abomination." If the confusion surrounding a single line on tax return forms this year is any indication, he's not likely to change that opinion soon.
The line that has already generated numerous headaches for the Internal Revenue Service and taxpayers has now moved on to become the center of a spat between the Treasury Department and a newspaper columnist.
Late Friday, Treasury spokeswoman Michele Davis issued a tartly worded news release rebutting assertions by New York Times columnist Paul Krugman that line 47 on this year's Form 1040 tax returns -- which the IRS says is meant to provide a tax credit -- would result in a bigger tax bite.
In his column, Krugman, a noted Princeton University economist, warned taxpayers that "they will discover that they owe $300 more in taxes than they expected" when they fill out their returns.
The IRS says the line is a place for taxpayers who did not get the full benefit of last summer's advance tax rebates to claim a tax credit. Taxpayers who got the full rebates, $300 for individuals and $600 for a married couple filing jointly, are told to leave the line blank.
"Contrary to the column's assertion, last summer's checks did not reduce refunds or increase tax bills," Davis said in the release headlined "Line 47 exists to give more money back to taxpayers" and "Krugman got it backwards in today's New York Times."
The line in question is Line 47 of IRS Form 1040, which parades as line 30 of Form 1040A and line 7 of Form 1040EZ. Earlier this month, the IRS said it had already seen more than 1 million erroneous returns filed because of the line and said the errors could delay refunds by a week or more.
On Form 1040, line 47 is in the tax and credits section, nestled between line 46, "Education credits. Attach Form 8863," and line 48, "Child tax credit (see page 37)." It reads: "Rate reduction credit. See the worksheet on page 36."
Talking heads say? Sometimes I am amazed by these guys. Can they really manage money? They don't seem to have clue or much of a "take charge" additude/direction.
"You buy stories that are simple and that are easy to understand and that have been there a long time," said Brian Pears, head of equity trading at Victory Capital Management. "You get very boring in an environment like this, because you don't want to get hurt."
You still have some pretty manic-depressive people," said James Volk, co-director of institutional trading at D.A. Davidson and Co. "One day there is good news out of Israel, one day there is bad news. Then there's good news on some accounting, bad news on others. And we are still getting some pre-announcements, which don't look so good."
When there's uncertainty, investors shoot first and ask questions later," said Kent Gasaway, who helps manage $2.5 billion for Kornitzer Capital Management.
The worries with the banks are that people don't know what their exposure is, Gasaway said. Manufacturing stocks "are responding to better economic news because they didn't get quite as expensive as the tech stocks," he added.
People are dumping any stock if there are any questions about bookkeeping," said Jon Burnham, who manages the $180 million Burnham Fund. "The market will be very volatile until people get more comfortable with financial reports."
http://story.news.yahoo.com/news?tmpl=story&u=/nm/20020222/bs_nm/markets_stocks_dc_503&cid=5...
Defense contractors-
Northrop Offers $6 Billion for TRW
NEW YORK (Reuters) - Northrop Grumman Corp. on Friday unveiled an unsolicited takeover bid of at least $6 billion for TRW Inc. that would create a powerhouse in satellite and missile-defense systems and challenge Boeing's ranking as the No. 2 U.S. defense contractor.
If accepted, the merger would move Northrop further into space systems, notably the battle management and missile defense nerve centers that are due for tens of billions of dollars of Pentagon outlays in coming years.
Northrop said it was prepared to offer $47 in stock for each TRW share, and indicated it might be willing to raise the bid. TRW said its management would "address" the proposal, and advised shareholders not to take any immediate action.
Wall Street appeared to embrace the idea of a higher bid. Shares of TRW surged 26.4 percent, or $10.50 to $50.30, in New York Stock Exchange trade, more than 6 percent above Northrop's offer price.
"It's a terrific fit," said Cai von Rumohr, analyst at SG Cowen. "It rounds out their portfolio and clearly cements them as a real heavyweight player."
Northrop shares fell $7.85, or 6.7 percent, to $109.95.
Northrop said that after combining the companies, it would separate TRW's auto parts business, which it said was not a good fit with either TRW or Northrop. The business produces nearly two-thirds of TRW's revenues, and Northrop's CEO said he had already spoken with a potential buyer.
TRW would boost Northrop's annual sales to between $26 billion and $27 billion, excluding the auto parts business, Northrop said.
To date, Northrop has been only a marginal player in the Bush administration's drive to build a layered defense against ballistic missiles that could be tipped with nuclear, chemical, or biological warheads.
TRW, on the other hand, is developing the command, control, and communications systems for launching interceptors and stitching together the sensors that detect enemy missiles. Along with Lockheed Martin and Boeing Co. , TRW is also developing an experimental, high-energy, space-based laser designed to destroy enemy rockets.
"It makes great sense, the timing is lousy," said Jon Kutler, president of Quarterdeck Investment Partners Inc.
TIMING IS EVERYTHING
Indeed, analysts and investors called Northrop's move aggressive on two fronts.
First, the offer came just two days after TRW Chief Executive David Cote, who masterminded a dramatic restructuring at the company, resigned to take the helm at Honeywell International . TRW shares fell about 10 percent following news of Cote's departure.
TRW expressed regret at the timing of the Northrop proposal, saying it came, "immediately following the unexpected departure of ... Cote, and the aberrationally low stock price that resulted."
A Honeywell spokesman said Cote's move had "no connection" to Northrop's planned bid for TRW.
Northrop's proposal also follows its completion of two acquisitions in the past year -- of Litton Industries and Newport News Shipbuilding -- that doubled revenues and made the contractor the world's No. 1 builder of warships.
"Northrop has an awful lot on its plate, digesting Litton and Newport News. But they've proven in the past that they won't let inconveniences stop them from going after targets of interest," Kutler said. "They are aggressive. They are opportunistic."
Northrop officials have touted their skills in integrating companies, calling it a "core" capability.
"We've had a strategic interest in TRW for a while," Northrop CEO Kent Kresa told Reuters, noting Northrop first approached TRW a few years ago. Kresa said he spoke with TRW Chairman Philip Odeen Thursday night regarding the offer.
Northrop's buying power appears strong, analysts said, noting its stock has carried the highest price in the industry until it dropped on Friday following the offer for TRW.
UPPING THE BID?
Northrop said its tax-free, $47-a-share offer represented a 22 percent premium over TRW's average share price in the last 12 months. Based on Thursday's closing price, Northrop is offering 0.398 of its shares for each TRW share.
The offer was made public in a typical "bear-hug" fashion in which Northrop's Kresa made public a letter to TRW management.
In the letter, Northrop indicated it would consider raising its bid. "We would welcome the opportunity to consider non-public information concerning TRW, and we are prepared to consider in our offer any enhanced values that may be demonstrated by such information," it said.
Northrop, maker of the B-2 stealth bomber and the Global Hawk unmanned spy plane, asked for an answer from TRW by Feb. 27. It said a definitive agreement could be reached by March 11 and a deal could be closed by the third quarter. It said it expected "minimal" antitrust problems.
Kresa said a higher bid would have to be based on information obtained through a due diligence review. "We're not willing to raise the bid based on the public information we have today," he said. "All that says is we would hope that TRW would allow us to do due diligence.
"Obviously, if there's more value than we can see from the public data, then that's a possibility," he said, referring to a higher offer.
Defense analysts said the Pentagon was likely to look favorably on a Northrop-TRW combination because it would create a horizontally integrated giant capable of rivaling Lockheed and Boeing.
Ranked by the total value of contract awards, Lockheed Martin was the top U.S. defense contractor last year; Boeing was No. 2; Northrop, combined with Newport News, was No. 3; and TRW was No. 7.
Another drug approval.
Friday February 22, 7:40 pm Eastern Time
Press Release
SOURCE: Newstream
Multimedia Available/FDA Approves Novartis Drug ZOMETA -- Zoledronic Acid for Injection -- for the Treatment of Cancer-Related Bone Complications
(BUSINESS WIRE)--
The U.S. Food and Drug Administration (FDA) today approved the Novartis drug ZOMETA® (zoledronic acid for injection) for the treatment of patients with multiple myeloma and patients with documented bone metastases from solid tumors, in conjunction with standard antineoplastic therapy.
These solid tumors include prostate cancer, lung cancer, breast cancer and other solid tumor types. In prostate cancer, patients should have progressed after treatment with at least one hormonal therapy.
The trials that led to the approval of ZOMETA mark the first time any bisphosphonate has demonstrated efficacy in treating bone complications in patients with prostate cancer, lung cancer and other solid tumors.
Further, ZOMETA offers patients, nurses and clinicians a convenient 4 mg, 15-minute infusion time.
You can reach the story directly by going to http://www.newstream.com/cgi-bin/display_story.cgi?5185
This multimedia news story is for free and unrestricted use on your news information site (and for print or broadcast too). Visit http://www.newstream.com to download video, audio, text, graphics and photos.
If you have any questions about the story, or about Newstream.com, please write to us at info@newstream.com.
--------------------------------------------------------------------------------
Contact:
Newstream.com, New York
info@newstream.com
Good Morning, Here is an email I got this morning.
Subject: Breaking News!
Date: Fri, 22 Feb 2002 13:45:20
Torbay Holdings Inc’s (OTC:BB TRBY)
52 Week Range 0.22-4.88
Issued Cap 17 M
Float 1 Million
· Biomechanics addresses Carpal Tunnel Syndrome in Mouse users
· PC mouse sales in excess of 100,000,000 pieces per year
· Price Premiums anticipated at 40-100% more than ergonomic mice
· The QuillTM Biomechanical Computer MouseTM to be aired on CNBC
TRBY’s Biomechanically designed computer mouse, The QuillTM and E-Quill-LiberatorTM are
designed to interface man and computer safely. Its pre-summer launch city and PC market
awareness program is firmly establishing TRBY as the world leader in biomechanical Computer
Solutions Technology. This has resulted in syndication of the story in the US and UK,
tremendous responses of congratulations, “when can I buy one” at the TRBY’s website, and
airing on CNBC and Discovery’s Health Channel being scheduled.
Carpal Tunnel Syndrome (CTS) will be recognized as the industrial plague of the 21st
Century that has come about due to what biomechanics now show to be flawed designs in the
so called ergonomic mice. Torbay’s UK Clinical Biomechanists discovered that the current
generation mice, where the hand is in the palm down position, create the physiological
environment for fatigue and other mousing limb injuries known as or associated with CTS.
They then invented a biomechanical solution that is so innovative it has just been granted
a patent. The design is simple yet elegant as it maintains the hand in the
biomechanically safe “handshake” position while keeping the angle of the wrist and hand
within a set angular relationship. It does not require any alteration as to how the
operator uses the mouse allowing for early and rapid market uptake.
>From its TRBY’s website survey at www.torbayholdingsinc.net, the early indications are that
if you are left handed you get left sided problems and if right handed, right sided
problems, indicating the mouse, not the keyboard, as the main problem; 60% of PC users who
report CTS-like symptoms do not seek medical advice but search for aftermarket solutions.
This “informed” market sector indicates a preparedness to pay some 40-100% more for a
solution that addresses their problem, and are actively seeking it. In addition, The
QuillTM in respecting the body’s biomechanics, will be made in left and right-handed
versions, directly addressing the dexterity and CTS needs of the estimated 12-36 million
left-handed individuals in a market of some 120 million mouse sales per annum. So as to
ensure the problem is addressed before it starts, The QuillTM will also be made in a
“child’s” size. Torbay is preparing for manufacture and sales of its high volume and high
margin products in anticipation of defining the safety issues in the PC industry with its
biomechanical technology, just like ABS and airbags did in the car industry.
Torbay Holdings Inc, “Teaching Computers to Work with People”
SAFE HARBOR STATEMENT
emailer is an independent electronic publication providing information on selected public
companies. Certain companies profiled by emailer pay consideration in cash and/or stock to
emailer for the electronic dissemination of company information and, in some cases, web
site development. emailer was retained as a consultant to TRBY for one year, pursuant to a
written agreement that provides for the immediate payment of 50,000 shares of common stock
of TRBY, free trading, unencumbered for its services, including the electronic
dissemination of information concerning the profiled company. emailer did not receive any
other compensation, of any kind, for its services other than stated herein. emailer is not
a registered investment advisor or a broker dealer. emailer has been advised that the
investments in companies profiled are considered to be high risk and use of the information
provided is for reading purposes only if anyone decides to act as an investor they are
advised not to invest without the proper advisement from an attorney or a registered
financial broker if any party decides to participate as an investor then it will be that
investor’s sole risk. emailer has also been advised that the purchase of such high-risk
securities may result in the loss of some or all of the investment. All information
provided by the profiled companies may include information provided by outside sources,
such as research reports, public filings or computer databases and information provided to
emailer by management of the profiled company. All information is provided by the companies
profiled and emailer makes no representations, warranties or guarantees as to the accuracy
or completeness of the disclosure by the profiled companies. Investors should not rely
solely on the information presented. Rather, investors should use the information provided
by the profiled companies as a starting point for doing additional independent research on
the profiled companies in order to allow the investor to form his or her own opinion
regarding investing in the profiled companies. Factual statements made by the profiled
companies are made as of the date 2/22/2002 and are subject to change without notice. The
receipt of this information shall not create, under any circumstances, any implication that
there has been no change in the affairs of the company profiled since the date of review.
Investing in micro-cap securities is highly speculative and carries an extremely high
degree of risk. It is possible that an investor's entire investment may be lost or impaired
due to the speculative nature of the companies profiled. emailer makes no recommendation
that the securities of the companies profiled should be purchased, sold or held by
individuals or entities that learn of the profiled companies through emailer. Investing in
micro-cap securities is highly speculative and carries an extremely high degree of risk. It
is possible that an investor's investment may be lost or impaired due to the speculative
nature of the companies profiled. Certain of the statements contained in this news release
may be forward-looking statements within the meaning of The Private Securities Litigation
Reform Act of 1995. These statements may be identified by such terms as ``expect,''
``believe,'' ``may,'' ``will,'' and ``intend'' or similar terms. emailer Capital
Corporation or its affiliates may have a position in the securities mentioned herein and
may make purchases or sales thereof. For initial or continued listing, a company must
satisfy one of the following to be in compliance; the net tangible asset requirement (net
tangible assets means total assets, excluding goodwill, minus total liabilities), the
market capitalization requirement, or the net income requirement. Public float is defined
as shares that are not held directly or indirectly by any officer or director of the issuer
or By any other person who is the beneficial owner of more than 10 percent of the total
shares outstanding. Round lot holders are considered holders of 100 shares or more. If
operating history is less than one year, initial listing requires market capitalization of
at least $50 million.
to be removed from our subscriber lists please click here
Poet, congrats.
What happened to the smooches, LOL?
Good Morning,
Had to cut out on the chat last night. Work called.
But before that we talked about CSCO some. I had a mental buy range of $15 a while back, then quit watching it. Now, in after dicussing in chat, looks like that buying range could be $11- $13.50.
Street shooter memtioned some bottom feeder scans. WCOM and CFLO were 2 that have been mentioned in BTS before. Also MONI was mentioned along with a couple of others that I did not write down. Maybe street can post them here later.
Another one mentioned was TRAC. The club picked this one just before the last run, and currently is worth wacthing- short term may see 2.75.
Well, Time to head to work- Hope all your trades are profitable-
The next email-
From: wsch6000@eudoramail.com / Block Address / Add to Address Book
Subject: WSCH : A Revolutionary Acne Treatment and More RJWZ
Date: Thu, 21 Feb 2002 23:58:45 -1800
Reply-to: wsch6000@eudoramail.com
Special Alert : WASATCH PHARMACEUTICALS (OTCBB: WSCH)
TOP 4 REASONS TO BUY WSCH
1. The products and medical therapies developed by WSCH represent possibly the most important breakthrough in the field of Dermatology in the last fifty years.
2. WSCH anticipates FDA approval on seven over-the-counter products within the next year, which will provide significant revenue in the retail drug market.
3. WSCH has experienced a success rate of 90% during clinical studies, completely eliminating skin disease from 90% of all patients treated.
4. By year five, WSCH plans to have annualized revenue over $525 million and over $125 million in EBIT. This does not take into account income from OTC products which will be substantial.
PROJECTIONS, OBJECTIVES AND STATISTICS
Over a five year period, AISC (WSCH's subsidiary) plans to establish 350 clinics in over 100 major population areas. The company plans to hire over 150 medical doctors for these clinics, train over 1,000 medical assistants and treat over 2,000,000 patients. Also by year five, WSCH plans to have annualized over $525 million in revenue and over $125 million in EBIT. This does not take into account income from OTC products which will be substantial.
As of 1991, there were approximately 14 million chronic acne and eczema patients annually in the United States, with the highest percentage between 18 to 44 years of age. The actual number of patients with any type of acne Is significantly higher. Seven billion dollars is spent annually on dermatological pharmaceutical products for these disorders.
In 1994, the teen population reached 25 million. During the next decade, it will grow at nearly twice the rate of the overall population (according to U.S. Census Bureau projections). Acne patients are primarily teenagers, whereas eczema patients range from infants to the elderly.
SYMBOL: WSCH
CURRENT PRICE: $0.059
52 WEEK HIGH: $27.50
52 WEEK LOW: $0.056
COMPANY BACKGROUND
Wasatch Pharmaceutical, Inc. is a fourteen year old company with a record of outstanding achievements in the field of Dermatology. Dermatology. Under the name of its subsidiary, American Institute of Skin Care (AISC), Wasatch has operated two prototype clinics for the last five years where the products and medical therapies have been tested and proven on hundreds of patients. The Company's activities have been centered on research in the area of serious skin diseases. A concurrent discovery and benefit is WSCH's dramatic success in the area of skin rejuvenation.
Seeing the high growth potential from major funding, WSCH elected to become a public company less than two years ago.
Wasatch's major successes in the area of skin diseases include:
Cystic Acne, Eczema, Seborrhea, Contact Dermatitis, Molluscum, Folliculitis, Acne Rosacea and less prevalent skin diseases.
Interestingly, these skin disorders account for more than 70% of all business in the field of dermatology for which there are very few (if any) safe, effective therapies like those developed by Wasatch.
Because the therapies developed by Wasatch dominate this area of medicine, WSCH has elected to market its products via company-owned clinics throughout the United States. This decision has resulted in the establishment of two research clinics in Utah for the purpose of implementing procedures within the clinics pursuant to testing and confirming the results that were achieved in past clinical trials. Due to its success rate of 90% on hundreds of patients over a five year period, WSCH's clinics are now on line with insurance providers independent of HMOs. Efforts to establish Preferred Providership status with HMOs are presently being pursued.
THIS JUST IN : WSCH BREAKING NEWS
Wasatch Pharmaceutical Inc. Announces a New Physician Marketing Campaign and Listing On German Stock Exchanges
MURRAY, Utah--(BUSINESS WIRE)--Nov. 27, 2001--Wasatch Pharmaceutical Inc. (OTCBB: WSCH - news) CEO Gary Heesch announced today a marketing campaign directed to physicians. A direct link has been established on a physician recruiting Web site making available therapies for the treatment of cystic acne, acne, folliculitis and skin rejuvenation. Physicians will find the benefits of these treatment therapies by logging on to the "X Acne" link at the Physician Search website. This physician search Web site typically receives over 200,000 hits per month. Mr. Heesch reminded, "Our treatment therapy products are also available via the AISC Online Store."
These skin treatment products come in kit form providing a 90-day supply to patients for the full treatment program. Included in the kit is an instructional video on the treatment therapy allowing the patient to use these products in their home. The therapies, when used as instructed, achieve a success rate of eradication in excess of 90% with no side effects of any consequence. Previously, these therapies and associated products were only available through the two prototype clinics in Utah. The availability of these products will open the way for family practitioners, pediatricians, internists and other primary care physicians to retain their patients under their care during the treatment of these common skin disorders. The benefit to insurance providers is the potential to save millions of dollars in reimbursement costs by freeing the physician and the patient from ongoing treatment.
In the coming year, six additional therapies will be made available for a broad range of skin disorders that are badly in need of successful therapies.
Gary Heesch also announced the listing of Wasatch Pharmaceutical stock on the Frankfurt and Berlin Exchanges in Germany. Active trading on these exchanges will take place upon the completion of a research report in Germany. Said Mr. Heesch, "We feel this is a significant event as Wasatch will gain wider exposure as a leader in dermatology and will put buying pressure on its stock to reflect the true value of a company that has committed years of research and development of products that allow people with serious skin disorders to live normal and more productive lives."
There may be forward-looking statements in this release. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including, without limitation, continued acceptance of the Company's products, increased levels of competition, new products introduced by competitors, changes in the rates of subscriber acquisition and retention, and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
A LOOK AT THE COMPETITION
Dermatologists are the primary competitors of WSCH's clinics. Dermatologists specialize in the treatment of skin disorders and prescribe medications to treat the disorder. However, competing products address the symptoms of acne and eczema, not the cause.
The competition's skin care treatments include prescription medications (oral and external use drugs prescribed by dermatologists and other doctors) and over-the-counter products.
Several common prescription medications include:
1) E-Mycin for oral and topical use, 2) Cleocin for oral and topical use, 3) Tetracycline for oral and topical use, and 4) Accutane for oral use only.
Over-the-counter acne medications include:
1) Clearasil and Oxy creams, 2) generic brand creams, 3) medicated pads, and 4) medicated soaps.
Many of the competition's oral medications have serious side effects.
Costs for competing treatments range from $2.50 for medicated soaps to $200 for Accutane oral medication prescription. Treatments are on-going. Over time a person can spend an unlimited amount of money on such treatments. An example would be someone who spent $1,500 for a 22 week program of Accutane which includes blood testing. Another example would be someone who has had acne for many years and has spent in excess of $34,000.
At this time there is no known competitor who treats the causes of these skin disorders and no competitor can claim a success rate equal to that of Wasatch's treatments.
A FINAL WORD ABOUT WSCH
With a proven success rate of 90% in a field that affects so many of our lives, Wasatch has clearly positioned itself in a market hungry and desperate for successful products and treatment. WSCH has recently expanded its marketing presence (as seen in the above press release) and will continue to aggressively broaden awareness over the near term. The listing of WSCH on the German stock exchange is another sign of the company's credibility and ambitious plans to establish itself as a major global player in the field of dermatology.
WSCH has taken on a completely different approach. By addressing the causes of skin disorders rather than the symptoms, WSCH will help to successfully eliminate skin disease altogether. Given the following:
1. Successful 14-year history and plans for expansion
2. Impressive revenue projections ($525 million+ annualized by year 5 and $125 million in EBIT)
3. Virtually unmatched success rate of 90%...
...and so much more, WSCH will certainly be watched by savvy investors for some time to come.
To be removed from future mailings, please reply to this email with "Remove" in the subject line
DISCLAIMER:
Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements."
Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. Emerging Growth Stock Alert advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice.
In compliance with the Securities Act of 1933, Section17(b), Emerging Growth Stock Alert discloses the receipt of $50,000 cash from a third party for the publication of this report and additional services related to WSCH. Be aware of an inherent conflict of interest resulting from such compensation. In addition, Emerging Growth Stock Alert intends to receive three million five hundred thousand unrestricted shares of WSCH from a third party for the publication of this report and additional services related to WSCH. Be aware of an inherent conflict of interest due to our intent to profit from the liquidation of these shares. Part or all of this position may be sold at any time, even after we have made positive statements regarding the above company. All factual information in this report was gathered from public sources, including but not limited to SEC filings, Company Press Releases, and the company's website at wasatchpharm.com. Emerging Growth Stock Alert believes this information to be reliable but can make no guarantee as to its accuracy or completeness. Use of the material within this email constitutes your acceptance of these terms.
KP, Yep. Still think that this stock has a chance. Lots of fear out there- and the media is playing on it.
~~~~~~ COMPX 2/22/02 ~~~~~~
Previous Close: 1716
1694 timhyma
1702 xxrayeyes
1723 Poet
Going early tonight
Thanks Joe, for the warning. I know is a scam, Just thought others may want to know what scam stock is being pumped.
Thanks Fred. Noticed it up on the T/A side. Did not buy in though.
~~~~~~ COMPX 2/21/02 ~~~~~~
Previous Close: 1775
1735 xxrayeyes
1741 alexed
1745 JXM
1767 timhyma
1790 Poet (even though I'm short)
1810 Matt
1815 Muell
1825 ez2
Know I'm Late, so will understand if I'm disqualified.
New York Driving Rules
Turn signals will give away your next move. A real Long Island
driver never uses them. Use of them in Massapequa may be illegal.
Under no circumstances should you leave a safe distance between
you and the car in front of you, or the space will be filled
in by somebody else putting you in an even more dangerous situation.
Crossing two or more lanes in a single lane-change is considered
"going with the flow."
The faster you drive through a red light, the smaller the chance
you have of getting hit.
Never get in the way of an older car that needs extensive bodywork.
Braking is to be done as hard and late as possible to ensurhat your
ABS kicks in, giving a nice, relaxing foot massage as the brake
pedal pulsates. For those of you without ABS, it's a chance
to stretch your legs.
Electronic traffic warning signs are not there to provide useful
information. They are only there to make Long Island look
high-tech, and to distract you from seeing the state police
radar car parked on the median.
Never pass on the left when you can pass on the right.
Speed limits are arbitrary figures, given only as suggestions,
and are apparently not enforceable during rush hour.
Always slow down and rubberneck when you see an accident,
or even if someone is just changing a tire.
Throwing litter on the roads adds color to the landscape and
gives Adopt-a-Highway crews something to clean up.
It is assumed that state police cars passing at high speed
may be followed in the event you need to make up a few
minutes on your way to work, or the beach.
Heavy snow, ice, fog, and rain are no reasons to change any
of the previously listed rules. These weather conditions are
God's way of ensuring a natural selection process for body
shops, junkyards, and new vehicle sales.
From: WallstreetSuggests8575d35@jindo.co.kr / Block Address / Add to Address Book
To: dujesh@
Subject: DECLUDE-ROUTING: FREE Report on Tech Stocks 7985FCmr5-129ZJoH7l17
Date: Wed, 20 Feb 2002 01:43:28 -0500
Free Breifing Regarding Tech Stocks
We are providing you this offer for investors.
If you no longer wish to receive such mailings or
have received this in error, please find the remove
instructions below. - Investor Offers
Dear Investor,
If you own ANY of today’s widely-held technology stocks,
then I urge you to read what I’m about to say IMMEDIATELY.
That’s because I’m recommending that you SELL three well-known
technology stocks today-and I want to give you all the
profit-protecting details immediately in my just-released
FREE online briefing. Quite simply, "Enronitis" is gripping
the market. Investors, Wall Street, and the media-already on
edge from the market malaise of the last 18 months-are now
SCARED TO DEATH that the Enron accounting plague will spread.
AND THAT MEANS you must pick and choose your investments very
carefully-or risk getting SNARED in the panic. Going forward,
any company with even a HINT of questionable accounting methods...
suspicious business practices...or just plain weak market
position is a target.
You don’t want to own those stocks-OR the three
I’m about to disclose. Period.
Before I reveal the details, however, let me introduce myself.
My name is Michael Murphy, and I’ve been analyzing technology
stocks for over 30 years-decades before it was "hip" to be a
tech investor or before Wall Street even found
Silicon Valley on the map!
I’ve led my Technology Investing readers to 59% profits in the
last 3 years alone (we beat the NASDAQ by 53%)...I sold Enron
from my mutual fund last summer at $30 because I couldn’t
figure out how the company made any money...and I publicly
warned investors about the looming Imclone disaster back in May,
months before the stock plunged over 80% and Congress opened a
House investigation.
NOW TODAY, I’M URGING YOU TO SELL THE FOLLOWING THREE STOCKS.
*Drug giant fighting Alzheimer’s,
Parkinson’s, multiple sclerosis,
cancer and a host of other deadly
diseases will continue to get nailed
for artificially inflating revenues.
This company is using off balance sheet
partnerships to prop-up bottom-line growth
numbers on its income statement...exactly
the type of AGGRESSIVE ACCOUNTING Wall Street
is punishing mercilessly. In the wake of the
Enron scandal, I wouldn’t touch it with a 10-foot pole!
Visit http://www.ppi-orders.com/index.htm?promo_code=1DJ208
to get its name-and all the details-in my FREE online briefing.
*This major-league wireless company is falling
behind FAST...and most investors have no earthly idea!
The problem? They’re betting on the second best wireless
technology...moving way too slowly in the shift to 3G
wireless services...and their investment cycle is BEHIND
that of their #1 competitor. Get out now, and reinvest
your money in the true wireless juggernauts set to clean
up from the real wireless boom. Details in my free briefing.
*This Communications big-shot is a surefire, SHORT-TERM THREAT.
Wall Street hates a disappointment...but that’s exactly what
they’re going to get when they realize management was too
optimistic in its March quarter earnings estimates. WHAT’S
MORE, this company’s desperate attempts to break into the
new high-growth areas of metro DWDM transport, next generation
SONET and optical switching have met with limited success...
making this the WEAK entry in an already tough communications
marketplace. Avoid this stock-and if you own it, SELL IT NOW.
Is there a chance you could own any of these losing stocks?
Want to know more?
Visit http://www.ppi-orders.com/index.htm?promo_code=1DJ208
to get their names-and all the details-FREE in my just released
online briefing, "Don’t Get Burned By Enronitis." In it, you’ll
find out everything you want to know about these 3 stocks
PLUS I’ll tell you where I’m putting my money instead today.
This briefing is ABSOLUTELY FREE, but it could SAVE YOU
thousands upon thousands of dollars in protected profits.
Don’t get burned again!
Visit http://www.ppi-orders.com/index.htm?promo_code=1DJ208
now and read your copy today.
Sincerely,
Michael Murphy
P.S. Wall Street’s on edge and weary investors are
looking for any excuse to dump stocks.
You don’t want to get caught holding the bag on
these 3 technology bombs. At least get the facts.
Go to Visit http://www.ppi-orders.com/index.htm?promo_code=1DJ208
now and download your copy of "Don’t Get Burned By Enronitis."
(Opt-Out Instructions)
This mailing is done by an independent marketing company.
You have received this email by either requesting more
information on one of our investment opportunities or
someone may have used your email address. To be removed
from our mailing list-Just send us an email by clicking below
(To Be Removed)
mailto:reverberate85@yahoo.com?subject=RemoveBriefingOffer
5860EiLQ1-201MEDO9290kDSj8-806hyjF2738qRVz4-962hMl46
5580GATa5-191ZcQV7461BquB6-496dCJo7083TUlE8-060xl45
Special Alert: SMMT has just completed a 10-1 forward split. This makes SMMT stock available to a larger audience, creating increased liquidity to support the growth of this dynamic company.
The stock market represents a TREMENDOUS opportunity for portfolio growth, especially in newly issued situations. SMMT represents one such situation. With the recent merger of Space Systems International and Stratcomm Media we have a promising opportunity for growth.
Company Name Stratcomm Media Ltd. (PINK: SMMT)
Current Price $0.006 (post 10-1 split)
52-Week High $0.175
52-Week Low $0.0029
Investment Highlights
The global market for satellite systems is in excess of $1 trillion dollars.
SMMT has independent sales agents in over 20 different countries.
SMMT has plans for a major marketing campaign this first quarter of 2002. This will help the company to meet its revenue projections and maintain a pace of rapid growth.
SMMT has worked with companies such as Qualcomm, Ericsson, and Globalstar Telecom.
Let's explore this exciting new company...
Dedicated Satellite Systems: More than $2 billion in proposals
SSI markets a turnkey remote sensing satellite system. While costs run upwards of $500 Million, the demand is there and SSI (SMMT) can fill it. Currently, SSI has a pending proposal with the Royal Thai Government to establish a Mapping and Remote Sensing Center which SSI will operate. One can only imagine the potential financial rewards of such a lucrative contract. This is a Trillion Dollar Market - There isn't a country on earth that could not use a series of dedicated satellites.
--------------------------------------------------------------------------------
SMMT's Clientele
Independent sales agents have been established in the following countries:
Saudi Arabia, Israel, Spain, Taiwan, Ukraine, Argentina, Canada, Brazil, Turkey, Germany, Indonesia, Thailand, Singapore, Venezuela, Kuwait, Greece, Hungary, Malaysia, Russia, Egypt, United States, & China.
SMMT's primary thrust is the integration of systems and their sub-components into an existing customer's infrastructure; for example, making images available for urban planning and highway development in Thailand. Additionally, SSI shall provide a potential customer with its capabilities through advertisement, meetings and attendance at trade fairs and conventions, such as The Paris Air Show, Singapore Air Show, Farnborough, Dubia, DOKTROI-Turkey, and more
SSI presently has clients in the U.S., Europe and the Far East:
1) State ministries that desire private complete satellite
systems for special purposes.
2) Oil companies that desire private satellite systems for
exploration and pipeline monitoring.
3) State organizations wishing to access space imagery
for database mapping.
--------------------------------------------------------------------------------
Recent Major News Developments
SSI Announces New Strategic Partnership
San Diego, Jan. 22 -- Space Systems International, Inc., a subsidiary of Stratcomm Media, Ltd. (SMMT), is pleased to announce the company has formed a strategic partnership with Eklectic Global. SSI believes the new alliance will open up new opportunities by leveraging and integrating the strengths of both SSI and Eklectic Global.
SSI Outlines Significant Marketing Campaign for 1st Quarter 2002
SAN DIEGO, Jan. 16 -- Space Systems International, Inc., a subsidiary of Stratcomm Media, Ltd. (OTC Bulletin Board: SMMT), is planning a significant marketing campaign in 1st Quarter 2002 to meet its long-term revenue projections. Current revenue projections are estimated at $2M to $5M in 2002 and growing to $35M in 2005. Approximately $1M in 2002 is coming from its Moscow operations via existing customers of our telecom network design and wireless deployment services. These projections do not include the sales of complete Satellite Imaging Systems that could return revenues of $200M plus over a 3-year period. Satellite Imaging Systems revenues, considered SSI's 'cash cow,' are not included in estimated projections until firm agreements are in place with 1 or more of 6 possible international customers.
--------------------------------------------------------------------------------
Technical Analysis
SMMT is trading near its 52 week low Its 52 week high is $0.175. At its current price of .01, this represents a tremendously exciting opportunity as word spreads of SMMT's merger with SSI. This is key for the 4000 shareholders of SMMT as it shows progress being made to appease shareholders.
With such a low market cap, and very few similar public companies, comparative analysis is not possible. However, with continued efforts working with multibillion dollar corporations such as QCOM, ERICY, and GSTRF, the future is limitless for SMMT as SSI strives to be the premiere Satellite Services company on the map.
To be removed from future mailings, please respond to this email with "Remove" in the subject line
DISCLAIMER:
Information within this email contains "forward looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21B of the Securities Exchange Act of 1934. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical fact and may be "forward looking statements."
Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through the use of words such as "projects", "foresee", "expects", "will," "anticipates," "estimates," "believes," "understands" or that by statements indicating certain actions "may," "could," or "might" occur. All information provided within this email pertaining to investing, stocks, securities must be understood as information provided and not investment advice. Emerging Growth Stock Alert advises all readers and subscribers to seek advice from a registered professional securities representative before deciding to trade in stocks featured within this email. None of the material within this report shall be construed as any kind of investment advice.
In compliance with the Securities Act of 1933, Section17(b), Wall Street Stockwatch discloses the receipt of one million unrestricted shares of SMMT from a third party for the publication of this report and additional services related to SMMT. Be aware of an inherent conflict of interest resulting from such compensation due to our intent to profit from the sale of these shares. Part or all of our position may be liquidated at any time, even after positive comments have been made regarding the above company. All factual information in this report was gathered from public sources, including but not limited to SEC filings, Company Press Releases, and the company's website. Wall Street Stockwatch believes this information to be reliable but can make no guarantee as to its accuracy or completeness. Use of the material within this email constitutes your acceptance of these terms.
To be removed from future mailings, please respond to this email with "Remove" in the subject line
From: avila0744v41@latinsite.com / Block Address / Add to Address Book
To: abuccini@
Subject: Build A Secure Financial Future 652l3
Date: Thu, 21 Feb 2002 03:14:51 -0500
6347mdXr7-481eYNF8054XUgs9-645pHYr2313sbMj2-710FQrE8007QFjs1-875kPYH1882yPl70
Building a Healthy Financial Future
STOP Investing The Same Old Ways!!!
Unlock the doors to STAGGERING PROFITS!
Tired of Stock Market Ups and Downs?
Mutual Funds Still on a Roller Coaster?
NOW is the Time to Embrace The ENERGY Markets!
Commodity Trading Makes Millions Every Day!
Powerful Profits Await YOU In The ENERGY Markets!!!
Fortunes will literally be made in the next few months!
Get Your FREE Energy Investment Information Packet at:
http://www.formortg.com/energy1
*We all NEED ENERGY...every day!
*We all USE Energy...every day!
*Your Life Resolves around ENERGY!
*Every Major Country in the world consumes ENERGY daily!
The Five Major Energy Markets are:
*Unleaded Gasoline
*Electricity
*Natural Gas
*Heating Oil
*Crude Oil
Recently, gasoline prices and crude oil prices were very low,
but are now rising again at the neighborhood pumps.
Let us show you how to profit from these price movements!
We can show you how many of our clients have turned a small
investment of only $10,000 into $50,000 or MORE in a very short
period of time! Isn't everyone looking for YIELDS like that?
($5,000 Minimum Investment)
HOW? Because WE ARE "The Energy Experts" and we are truly
Energy Market Specialists. We KNOW the Energy Markets!
We are an experienced, professional firm with over 25 years of
experience. Learn how our clients get the best results, and
receive the most professional care in the investment world today!
OPEC announced 11/1/01 they would be cutting oil production
because prices were just too low. OPEC AGAIN announced
on 12/28/01 to cut production another 6% starting 1/1/02!
How will that affect oil prices???
Prices reach extremes for reasons...
Do you want to know the reasons WHY?
Get Your FREE Energy Investment Information Packet at:
http://www.formortg.com/energy1
(Opt-Out Instructions)
You have received this email by either requesting more
information on one of our investment opportunities or someone may
have used your email address. To be removed from our mailing list
and to be automatically removed from any future mailings-
Go To The link above and at the bottom of the website
submit a request for Opt-Out!
7385MQRk2-922wPYy0532CXMl23
SCLD- going to the next level?
http://www.askresearch.com/cgi-bin/chart?symbol=scld&country=USA&size=640x480&months=6+m...